553
Views
0
CrossRef citations to date
0
Altmetric
Original Articles: Cancer Epidemiology

Do investments in cancer registry databases and tools bring added value? NORDCAN as an example

ORCID Icon, ORCID Icon & ORCID Icon
Pages 535-540 | Received 17 Apr 2023, Accepted 23 May 2023, Published online: 05 Jun 2023
 

Abstract

Background

In the 1990s, the large-scale collaboration Kreftbildet i Norden (KIN) drew attention to the need for timely cancer statistics for cancer control planning in the Nordic countries. Supported by the Nordic Cancer Union (NCU), a web-based version of NORDCAN was continually developed by the Association of Nordic Cancer Registries (ANCR) from 2003, with website support and hosting by the International Agency for Research on Cancer (IARC). Despite empirical evidence of its global reach, the question of whether recurrent investment in NORDCAN brings added value was raised; we sought to formally assess this.

Methods

Scientific value was determined by extracting publications citing NORDCAN from PubMed. We compared the funds allocated to the KIN project and later Nordic studies on cancer predictions and survival, with those allocated to NORDCAN.

Results

96 publications in 43 journals were retrieved. Two publication peaks, in 2010 and in 2016 relate to Nordic cancer survival and Danish age care projects, respectively. Papers citing NORDCAN increased substantially from 4 published in 2017 to the 24 papers in 2022. The integration of survival and prediction projects into NORDCAN reduced the costs of investment to one-quarter of the those required in earlier years, in real terms.

Discussion

User statistics and scientific output clearly points to NORDCAN bringing added value given resources expended, even with the additional costs imposed to ensure GDPR compliance. Research funding indicates that the databases and interactive tools are critical as both research and education resources. Nonetheless, a sustainable funding model is needed if NORDCAN is to continue to fulfill its utility in cancer control, health care planning and cancer research.

Acknowledgements

The Nordic Cancer Union (NCU) is acknowledged for their continuous financial support in the development of NORDCAN and running the secretariat.

The Cancer Registries forming the Association of Nordic Cancer Registries and staff at the Cancer Surveillance Branch, IARC are acknowledged for their professional support to the development of the NORDCAN interface since its inception and for volunteering staff time to the continuous update and harmonization of the underlying data.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are publicly available These data were derived from the following resources available in the public domain:

Pub Med: https://pubmed.ncbi.nlm.nih.gov/

The authors confirm that the data supporting the findings of this study are available within the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.